Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	28.89B
Revenue (ttm)	5.70B
Net Income (ttm)	1.38B
Shares Out	2.23B
EPS (ttm)	0.61
PE Ratio	21.34
Forward PE	20.16
Dividend	0.22 (1.73%)
Ex-Dividend Date	May 22, 2024

Volume	66,051,263
Average Volume	20,542,400
Open	12.68
Previous Close	12.65
Day's Range	12.51 - 13.06
52-Week Range	9.08 - 18.33
Beta	0.20
RSI	52.31
Earnings Date	Apr 22, 2025

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. It offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, desacetyl-7-aminocephalosporanic acid, and ursodeoxycholic acid. Yili Chuanning Biotechnology Co.,Ltd. was incorporated in 2010 and is based in Yining, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 2,881
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2023, SHE:301301's revenue was 4.82 billion, an increase of 26.24% compared to the previous year's 3.82 billion. Earnings were 940.56 million, an increase of 128.56%.